Pharmaceutical compositions including nano-sized active agent

• US 20080026062A1
• Filed: 07/31/2006
• Published: 01/31/2008
• Est. Priority Date: 07/31/2006
• Status: Abandoned Application

• Current Assignee: Hewlett-Packard Development Company, L.P. (HP Inc.)
• Original Assignee: Hewlett-Packard Development Company, L.P. (HP Inc.)
• Inventors: Rivera, Leslie, Farr, Isaac, Figueroa, Iddys D., Kane, Kevin Michael, Aponte, Mirayda, Tirado, Saul, Valentin-Sivico, Javier, Diaz-Felipe, Ricardo G.
• Application Number:
  US11/496,873
• Publication Number:
  US 20080026062A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds

Abstract

The present invention is directed to a particulate pharmaceutical composition. The particulate pharmaceutical composition can comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical composition can be micronized or in the form of a film that can be rolled up. If micronized, the individual micron-sized particles can have a plurality of nano-sized particles present in the micron-sized particles.

Claims

1. A particulate pharmaceutical composition, comprising:

a water-soluble or partially water-soluble polymer matrix; and

a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix, wherein said particulate pharmaceutical composition is micronized, thereby forming individual micron-sized particles having a plurality of nano-sized particles present in the micron-sized particles.

2. The composition of claim 1, wherein the individual micron-sized particulates are enclosed by a capsule or are pressed into a tablet.

3. The composition of claim 1, wherein the active agent is selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, and combinations thereof.

4. The composition of claim 1, wherein the average size of the nano-sized sparingly water-soluble to water-insoluble active agent is less than 1500 nm.

5. The composition of claim 1, wherein the water-soluble polymer matrix comprises pullulan, polyethylene oxide, polyethylene glycol, block copolymers based on ethylene oxide and propylene oxide, polyvinyl pyrrolidone, cellulose ethers such as methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, hydroxylethylmethylcellulose, sodium carboxymethylcellulose, and aliphatic polyesters such as polylactide, poly(E-caprolactone), polyglycolide, poly(DL-lactide-co-glycolide), and combinations thereof.

6. The composition of claim 1, wherein the water-soluble polymer matrix comprises pullulan.

7. The composition of claim 1, wherein the pharmaceutical composition is substantially dissolvable in simulated intestinal fluid in less than 65 minutes when stirred at 75 rpm.

33. A method of using a particulate pharmaceutical composition, comprising administering to a subject the pharmaceutical composition of claim 1.

34. The method of claim 33, wherein the step of administering is by oral delivery.

35. The method of claim 33, wherein the subject is human.

8. A rolled pharmaceutical composition, comprising:

a water-soluble or partially water-soluble polymer matrix; and

a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix, wherein said pharmaceutical composition in the form of a rolled up film.

9. The composition of claim 8, wherein the rolled-up film is prepared by a roll-to-roll process.

10. The composition of claim 8, wherein the active agent is selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, and combinations thereof.

11. The composition of claim 8, wherein the film of the rolled up film has a first side and a second side, wherein the active agent is more concentrated at the first side than the second side.

12. The composition of claim 8, wherein the water-soluble polymer matrix comprises pullulan, polyethylene oxide, polyethylene glycol, block copolymers based on ethylene oxide and propylene oxide, polyvinyl pyrrolidone, cellulose ethers such as methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, hydroxylethylmethylcellulose, sodium carboxymethylcellulose, and aliphatic polyesters such as polylactide, poly(E-caprolactone), polyglycolide, poly(DL-lactide-co-glycolide), and combinations thereof.

13. The composition of claim 8, wherein the water-soluble polymer matrix comprises pullulan.

14. The composition of claim 8, wherein the pharmaceutical composition is substantially dissolvable in simulated intestinal fluid in less than 65 minutes when stirred at 75 rpm.

15. A method of making a pharmaceutical composition, comprising:

a) dissolving a sparingly water-soluble to water-insoluble active agent in a solvent system comprising at least one organic solvent to form a dissolved active agent;

b) applying the dissolved active agent to a water-soluble polymer matrix;

c) at least partially dissolving the polymer matrix to form a paste containing the active agent and the polymer matrix;

d) evaporating the organic solvent to form a nano-sized precipitate of the active agent, wherein the nano-sized precipitate is dispersed in the polymer matrix; and

e) drying the polymer matrix containing the nano-sized precipitate.

16. The method of claim 15, further comprising the step of rolling up the polymer matrix containing the nano-sized precipitate.

17. The method of claim 15, further comprising the step of micronizing the polymer matrix containing the nano-sized precipitate to form micron-sized particulates, wherein the micron-sized particulates have a plurality of nano-sized particles of active agent present therein.

18. The method of claim 17, further comprising the step of enclosing the micron-sized particulates into a capsule or pressing the micron-sized particulates into a tablet.

19. The method of claim 15, wherein the active agent is selected from amiodarone HCL, atorvastatin, candesartan, carvedilol, clopidogrel bisulfate, dipyridamole, eprosartan mensylate, felodipine, furosemide, isradipine, lovastatin, metolazone, propafenone HCL, quinapril, ramipril, simvastatin, trandolapril, valsartan, clozapine, entacapone, fluphenazine, fluvoxamine, imipramine, olanzapine, paroxetine, sertraline, triazolam, zaleplon, ziprasidone, acyclovir, amphotericin B, amprenavir, cefdinir, cefixime, ceftazidime, clarithromycin, didanosine, efavirenz, ganciclovir, itraconazole, melfloquine, norfloxacin, nystatin, ritonavir, saquinavir, tenofovir disoproxil fumarate, beclomethasone dipropionate, bosentan, budesonide, fexofenadine, flunisolide, fluticasone, loratadine, mometasone, salmeterol xinafoate, triamcinolone acetonide, zafirlukast, celecoxib, diclofenac sodium, dihydroergotamine mesylate, ergoloid mesylates, ergotamine tartrate, fentanyl citrate, nabumetone, azathioprine, carboplatin, cisplatin, cyclosporine, docetaxel, etoposide, flurouracil, irinotecan, letrozole, melphalan, mitotane, paclitaxel, pimecrolimus, sirolimus, tacrolimus, valrubicin, ethinyl estradiol, danazol, follotropin beta, medroxy-progesterone, methyl-testosterone, raloxifene HCL, sildenafil citrate, testosterone, calcitrol, dronabinol, famotidine, glyburide, isotretinoin, megestrol, modafinil, nimodipine, pioglitazone, propofol, thalidomide, betamethasone, triamcinolone, piroxicam, glimepiride, glipizide, digoxin, prednisolone, indomethacine, nadolol, fluconazol, cisapride, ibuprofen, acetaminophen, carbamazepine, nifedipine, ketoprofen, and derivatives, prodrugs, mixtures, and combinations thereof.

20. The method of claim 15, wherein the step of applying the dissolved active agent is by a printing process.

21. The method of claim 20, wherein the printing process is an ink-jetting process.

22. The method of claim 20, wherein the printing process is an electrostatic printing process.

23. The method of claim 15, wherein the solvent system comprises an alcohol, a chlorinated solvent, a ketone, or combinations thereof.

24. The method of claim 15, wherein the solvent system comprises chloroform, ethanol, methanol, acetone, acetonitrile, or combinations thereof.

25. The method of claim 15, wherein the polymer matrix comprises pullulan, polyethylene oxide, polyethylene glycol, block copolymers based on ethylene oxide and propylene oxide, polyvinyl pyrrolidone, cellulose ethers such as methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, hydroxylethylmethylcellulose, sodium carboxymethylcellulose, and aliphatic polyesters such as polylactide, poly(E-caprolactone), polyglycolide, poly(DL-lactide-co-glycolide), and combinations thereof.

26. The method of claim 15, wherein the polymer matrix comprises pullulan.

27. The method of claim 15, wherein the polymer matrix is in the form of a film before being at least partially dissolved.

28. The method of claim 15, wherein the step of at least partially dissolving the polymer matrix is performed by placing water in contact with the polymer matrix.

29. The method of claim 15, wherein the step of at least partially dissolving the polymer matrix occurs simultaneously with the step of applying the dissolved active agent.

30. The pharmaceutical composition produced in accordance with the method of claim 15.

31. The pharmaceutical composition of claim 30, in a micronized form.

32. The pharmaceutical composition of claim 30, in a film form.